Protara Therapeutics Inc
TARA
NASDAQ
Biotechnology
$3.97
USD
+0.03 (+0.76%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $233.72M
Volume 332.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-70.02M
TTM
-37.7%
YoY
Operating Cash Flow
$-66.13M
TTM
-47.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.8 | 5.2 | 6.0 | 6.1 | 6.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 16.6 | 14.8 | 19.1 | 19.6 | 23.3 |
Operating Income | -16.6 | -14.8 | -19.1 | -19.6 | -23.3 |
EBITDA | -16.5 | -14.7 | -19.0 | -19.5 | -23.3 |
Other Income / Expense | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
Total Other Income / Expense | 1.6 | 1.5 | 1.8 | 1.8 | 1.7 |
Income Before Income Taxes | -15.0 | -13.3 | -17.3 | -17.8 | -21.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -15.0 | -13.3 | -17.3 | -17.8 | -21.7 |
Consolidated Net Income / Loss | -15.0 | -13.3 | -17.3 | -17.8 | -21.7 |
Net Income Attributable to Common Shareholders | -15.0 | -13.3 | -17.3 | -17.8 | -21.7 |
Basic EPS | -$0.35 | -$0.31 | -$0.38 | -$0.31 | -$0.36 |
Diluted EPS | -$0.35 | -$0.31 | -$0.38 | -$0.31 | -$0.36 |
Basic Shares Outstanding | 42.3M | 42.3M | 46.1M | 57.5M | 61.0M |
Diluted Shares Outstanding | 42.3M | 42.3M | 46.1M | 57.5M | 61.0M |